These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

497 related items for PubMed ID: 15477438

  • 1. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
    Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH.
    Arch Intern Med; 2004 Oct 11; 164(18):2024-30. PubMed ID: 15477438
    [Abstract] [Full Text] [Related]

  • 2. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH.
    J Bone Miner Res; 2005 Sep 11; 20(9):1507-13. PubMed ID: 16059622
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
    Marcus R, Wang O, Satterwhite J, Mitlak B.
    J Bone Miner Res; 2003 Jan 11; 18(1):18-23. PubMed ID: 12510801
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.
    J Am Geriatr Soc; 2006 May 11; 54(5):782-9. PubMed ID: 16696744
    [Abstract] [Full Text] [Related]

  • 7. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA.
    J Bone Miner Res; 2004 May 11; 19(5):728-36. PubMed ID: 15068495
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide.
    Crans GG, Silverman SL, Genant HK, Glass EV, Krege JH.
    Arthritis Rheum; 2004 Dec 11; 50(12):4028-34. PubMed ID: 15593198
    [Abstract] [Full Text] [Related]

  • 10. The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women.
    Oglesby AK, Minshall ME, Shen W, Xie S, Silverman SL.
    J Rheumatol; 2003 Jul 11; 30(7):1579-83. PubMed ID: 12858462
    [Abstract] [Full Text] [Related]

  • 11. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec 11; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD, Hanley DA, Lorraine JK, Yu M.
    Clin Ther; 2007 Sep 11; 29(9):2055-67. PubMed ID: 18035204
    [Abstract] [Full Text] [Related]

  • 14. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH.
    Bone; 2006 Aug 11; 39(2):237-43. PubMed ID: 16563890
    [Abstract] [Full Text] [Related]

  • 15. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial.
    Qu Y, Wong M, Thiebaud D, Stock JL.
    Curr Med Res Opin; 2005 Dec 11; 21(12):1955-9. PubMed ID: 16368046
    [Abstract] [Full Text] [Related]

  • 16. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
    Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R.
    J Bone Miner Res; 2001 May 11; 16(5):925-31. PubMed ID: 11341338
    [Abstract] [Full Text] [Related]

  • 17. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT, Christensen PM, Ejersted C, Langdahl BL.
    Basic Clin Pharmacol Toxicol; 2004 Jun 11; 94(6):260-70. PubMed ID: 15228497
    [Abstract] [Full Text] [Related]

  • 18. Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index.
    Genant HK, Siris E, Crans GG, Desaiah D, Krege JH.
    Bone; 2005 Aug 11; 37(2):170-4. PubMed ID: 15961357
    [Abstract] [Full Text] [Related]

  • 19. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ.
    Arthritis Rheum; 2008 Jun 11; 58(6):1687-95. PubMed ID: 18512789
    [Abstract] [Full Text] [Related]

  • 20. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
    Seeman E.
    Curr Opin Rheumatol; 2006 Jun 11; 18 Suppl 1():S17-20. PubMed ID: 16735841
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.